An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers

• Published in: Breast cancer (Tokyo, Japan) Vol. 30; no. 5; pp. 703 - 713
• Main Authors: Fukui, Reiko, Watanabe, Takahiro, Morimoto, Koji, Fujimoto, Yukie, Nagahashi, Masayuki, Ishikawa, Eri, Hirota, Seiichi, Miyoshi, Yasuo
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.09.2023
• Subjects: Cancer Research; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Surgery; Surgical Oncology; Endocrine therapy; Breast cancer; Tumor-infiltrating lymphocytes; FOXP3; CD8
• DOI: 10.1007/s12282-023-01462-5
• ISSN: 1340-6868

Background The reason for the poor prognosis of estrogen receptor (ER) + /human epidermal growth factor receptor 2 (HER2)− breast cancer patients with high levels of tumor-infiltrating lymphocytes (TILs) is poorly understood. The association between TILs and response to neoadjuvant endocrine therapy (NET) was examined. Methods We recruited 170 patients with ER + /HER2− breast cancer who were treated with preoperative endocrine monotherapy. TILs were evaluated before and after NET, and their changes were noted. Furthermore, T cell subtypes were examined using CD8 and FOXP3 immunohistochemical analyses. Neutrophil and lymphocyte counts in the peripheral blood were analyzed with reference to TIL levels or changes. Responders were defined as Ki67 expression levels ≤ 2.7% after treatment. Results Post-treatment ( p  = 0.016), but not pre-treatment ( p  = 0.464), TIL levels were significantly associated with the response to NET. TIL levels increased significantly after treatment among non-responders ( p  = 0.001). FOXP3 + T cell counts increased significantly after treatment in patients with increased TILs ( p  = 0.035), but not in those without increased TILs ( p  = 0.281). Neutrophil counts decreased significantly after treatment in patients without increased TILs ( p  = 0.026), but not in patients with increased TILs ( p  = 0.312). Conclusion An increase in TILs after NET was significantly associated with a poor response to NET. Given that FOXP3 + T-cell counts increased, and neutrophil counts did not decrease in patients with increased TILs after NET, the induction of an immunosuppressive microenvironment was speculated to play a role in the inferior efficacy. These data might partially indicate the involvement of the immune response in the efficacy of endocrine therapy.